CPT® Code 85025

Last Updated: February 2026 | Verified for 2026 AMA, CPT & CMS Guidelines

Quick Reference: CPT 85025

• What it is: CPT 85025 is an automated complete blood count that includes an automated WBC differential. By definition it captures the CBC “core” (RBC, WBC, hemoglobin, hematocrit, platelet count and related indices) plus automated categorization of WBC subtypes. Documentation guidance for CBC usage appears in Medicare contractor education and clinical billing guidance .
• Single comprehensive service: 85025 is billed as a single code for the full automated CBC-with-diff service. Unbundling the differential (manual or automated) or separately billing overlapping CBC elements is generally inappropriate and commonly blocked by coding edits and policy guidance .
• Coverage principle: Medicare coverage is anchored in NCD 190.15 (Blood Counts), which supports CBC testing for diagnosis/management of relevant conditions and treats “no-indication” testing as screening and non-covered .
• Common denial drivers: Missing/unsupported ICD-10 indications, “routine screening” diagnoses, duplicate same-day billing without modifier 91, or billing overlapping hematology codes together contrary to NCCI policy .
• Key modifiers: Modifier 91 (true clinical repeat same day) may be needed when a second CBC is medically necessary. Modifier QW applies only when 85025 is performed using a CLIA-waived method and the billing context requires QW reporting (most CBC analyzers are not waived) . CPT 85025 is one of the most frequently ordered laboratory services because it provides a rapid, standardized snapshot of hematologic status. Clinically it is used to evaluate anemia, infection/inflammation, marrow suppression, bleeding risk signals, and systemic disease effects on blood cells. From a coding standpoint, 85025 is also “high-scrutiny” because it is high-volume and frequently included in pre-operative, emergency, oncology, and inpatient protocols. That combination can generate denials if documentation, diagnosis selection, and repeat-testing logic are not aligned to coverage and bundling rules.

This 2026 guide focuses on correct use of CPT 85025 in real billing environments: how to describe what the code includes, how to document and justify medical necessity, what Medicare expects under NCD 190.15, how NCCI rules prevent unbundling of the differential, and when modifiers (especially 91 and QW) are legitimately applied.

1. Definition & Components of CPT 85025

CPT 85025 is defined as an automated complete blood count with automated WBC differential. Operationally, it represents an analyzer-based panel that measures multiple parameters from a single blood specimen and reports both total counts and WBC subtype distributions. Medicare education and billing guidance for hematology contexts reinforces the expectation that the CBC and differential components are treated as a single service when reported as 85025 .

What is included when 85025 is performed

While individual analyzers and laboratory information systems may display different layouts, a typical automated CBC with differential includes the following categories:

• Red cell line: RBC count, hemoglobin, hematocrit, and commonly RBC indices (MCV, MCH, MCHC, RDW).
• White cell line: Total WBC count plus an automated differential that categorizes WBC subtypes (commonly neutrophils, lymphocytes, monocytes, eosinophils, basophils; many systems also report immature granulocytes or other flags depending on configuration).
• Platelet line: Platelet count and, depending on instrument/reporting, platelet indices (e.g., MPV). The billing point is not whether every index is itemized on the printed report; it is that 85025 is a single comprehensive automated service. Attempting to separately bill overlapping hematology codes in addition to 85025 (for the same specimen/date) is a frequent cause of denials and recoupments. NCCI policy is particularly important here because it frames the CBC-with-diff as a bundled service and identifies inappropriate code-pair combinations that would amount to duplicate payment .

Practical compliance note: Many laboratories perform reflex smear review or additional internal checks when analyzers flag abnormal results. Under NCCI policy logic, these internal steps generally do not convert an automated CBC-with-diff into separately billable manual differential services unless a distinct, separately ordered and reportable service is performed consistent with policy guidance .

2. Documentation & Medical Necessity

For CPT 85025, the “medical necessity” story is established by three aligned elements: (1) an order, (2) a clinical indication documented in the medical record, and (3) an ICD-10 code on the claim that accurately represents that indication. Medicare’s coverage framework for blood counts emphasizes that CBC testing must be tied to diagnosis/management needs rather than performed as a general screen for asymptomatic patients .

Required documentation elements

• Provider order: A documented request for CBC with differential (or an order that reasonably implies it, depending on setting). Contractor guidance in hematology/oncology contexts emphasizes that orders and clinical records should make the laboratory need apparent .
• Clinical reason (chart narrative): A note that links symptoms, findings, risk factors, or treatment protocols to the need for CBC evaluation (e.g., fatigue/pallor → anemia evaluation; fever → infection workup; chemotherapy → marrow suppression monitoring).
• ICD-10 alignment: A diagnosis code (or multiple codes) that best represents the reason the test is being performed. Under Medicare NCD logic, “screening-only” diagnoses are vulnerable to denial because the NCD treats testing without relevant signs/symptoms/management needs as screening .

Medical necessity: diagnostic vs screening framing

In day-to-day billing, the biggest preventable mistake is submitting CBC claims under an annual exam or “general wellness” diagnosis without a problem-oriented indication. Medicare’s NCD 190.15 explains that blood count testing is covered when used to diagnose or manage disease, but that testing without an expected abnormality is screening and not covered . That does not mean a symptom must be dramatic; it means the record should support a reason that makes a blood count clinically relevant.

In commercial payer environments, coverage rules can be similar or sometimes more permissive, but many payers still use diagnosis-based edits. For example, a payer policy may explicitly list routine or preventive diagnoses as non-supportive for certain lab services. Molina’s Clinical Diagnostic Laboratory Services policy is an example of a payer reference that discusses reimbursement and coding expectations for laboratory services, including the importance of coverage logic and claim consistency .

CLIA documentation hygiene

Separately from clinical necessity, laboratories must meet CLIA billing requirements. If testing is performed by the lab, the lab’s CLIA certification and claim compliance must match the complexity of the method. In California, Medi-Cal manuals emphasize documentation and program requirements for laboratory billing, including the need for proper claim data elements and medical necessity support . Even when the medical indication is strong, CLIA-related claim issues can lead to preventable denials.

3. Medicare & Payer Policies (Coverage, Screening, Denials)

Medicare is the most important reference point for 85025 policy because it provides a national coverage framework in NCD 190.15 and because many non-Medicare payers model their claim edits on Medicare logic. NCD 190.15 describes indications and limitations for blood count testing, including the screening limitation that is frequently relevant to denials .

Medicare: what NCD 190.15 functionally does

In practical terms, NCD 190.15 does three things that impact claims:

• Defines the covered purpose: blood counts are covered to diagnose or manage conditions where blood cell abnormalities are relevant.
• States a screening limitation: tests in asymptomatic patients without an expected abnormality are treated as screening and are not covered .
• Supports diagnosis-based edits: Medicare claim systems use diagnosis codes to assess whether a claim matches the NCD’s medical-necessity framework. When the diagnosis code does not fit the covered rationale, denial risk increases. This leads to a simple operational rule for billing teams: do not treat a CBC as a routine “default” order for every visit unless the documentation establishes a problem-oriented reason. In high-frequency settings (oncology, dialysis, ICU, ED), the reason is usually obvious. In primary care “wellness” settings, it may not be, and that is where documentation/coding discipline matters most.

NCCI bundling: why “extra codes” trigger denials

Even when the CBC is covered, payment can be reduced or denied if the claim structure violates bundling logic. CMS’s NCCI Policy Manual for pathology and laboratory services provides guidance on code combinations that represent duplicate billing or unbundling. For automated CBC-with-diff, the manual is used to support the concept that you should not bill overlapping or component hematology services in addition to 85025 for the same encounter, because it is duplicate payment for included work .

Importantly, NCCI logic is not simply “administrative.” It reflects a clinical workflow assumption: if the physician orders an automated CBC with differential, and the analyzer and lab processes deliver that service, the billing should represent the one combined service—not multiple separately priced fragments of the same work.

State Medicaid: administrative rules plus national logic

State programs typically incorporate Medicare-like medical-necessity principles and also impose administrative rules through provider manuals and coverage policies. For example, Medi-Cal laboratory billing guidance underscores the importance of correct billing structures and appropriate documentation for laboratory services . Florida Medicaid’s Laboratory Services Coverage Policy is another example of a state-level reference that defines coverage structure and program expectations for lab billing .

The takeaway for multi-state organizations is that the “big three” denial drivers are consistent: non-supportive diagnoses (screening logic), code-pair conflicts (bundling/unbundling), and administrative compliance issues (CLIA, required claim elements, program-specific billing instructions).

4. Modifiers, CLIA, and Repeat Testing (QW, 91)

For 85025, two modifiers matter most in routine compliance: QW (rare, method-dependent) and 91 (repeat clinical testing, scenario-dependent). Other modifiers are usually either inapplicable or uncommon for CBC billing in standard settings.

Modifier QW: CLIA-waived method only

Modifier QW indicates that the laboratory test was performed using a CLIA-waived method in a waived testing environment. For CBC, this is not the default state. CBC testing is generally moderate complexity, and most hematology analyzers used by hospital and reference labs are not waived. However, CMS and federal guidance recognize certain waived test implementations, and the CDC’s CLIA waived tests list is a key reference for determining whether 85025 is waived in specific method contexts .

In addition to the CDC waived list, CMS transmittals and guidance documents are used to operationalize waived test updates and billing instructions. CMS’s “New Waived Tests” guidance (CR/MM references) is commonly cited for effective dates and billing expectations when codes are recognized as waived for specific devices/methods .

Billing rule-of-thumb: Add QW only when you can defend it with method documentation (waived device/method) and when the payer requires QW for waived recognition. Do not add QW “just in case.” Incorrect use can trigger denials and, in audits, can be interpreted as misrepresentation of testing complexity.

Modifier 91: repeat clinical diagnostic test (same day)

Modifier 91 is used when the same laboratory test is repeated for the same patient on the same date of service to obtain additional clinical information (not because the lab had a technical failure). For example, a second CBC might be clinically necessary after significant bleeding, after transfusion, during rapid clinical deterioration, or to confirm/monitor a critical abnormal result. The purpose of 91 is to prevent a legitimate second test from being denied as an accidental duplicate.

Documentation expectation: If you bill a second 85025 with 91, the record should show why the repeat was clinically reasonable: a change in condition, new clinical question, or time-sensitive monitoring need. This aligns with Medicare’s general “reasonable and necessary” framework under NCD logic for blood counts .

Modifiers 26 and TC: generally not applicable to 85025

In most Medicare and payer contexts, 85025 is treated as a global laboratory service rather than a service split into a technical and professional component. In day-to-day billing, that means appending -26 or -TC is generally not appropriate for routine automated CBC results. If a payer expects professional interpretation, that is typically captured through the clinician’s E/M service rather than a separate CBC professional component.

5. Comparison: 85025 vs 85027 and Medicare G-codes (Conceptual)

The most common confusion is between 85025 and 85027. The distinguishing feature is the differential: 85025 includes an automated WBC differential; 85027 does not. Conceptually:

• 85025: Automated CBC + automated differential.
• 85027: Automated CBC without differential. From a compliance standpoint, you generally should not bill both on the same day for the same patient specimen/episode, because that would be duplicative. NCCI policy frameworks exist to prevent payment for code combinations that represent overlap or component billing rather than distinct services .

Medicare also has HCPCS G-codes historically used in niche contexts (often described as CBC configurations without platelets), but those are not the main decision point for most outpatient and hospital labs. In current operations, organizations should focus on the order and the performed service: if the differential was performed and reported as part of the automated CBC service, 85025 is the appropriate CPT representation; if no differential was performed/reported, 85027 is the closer match.

6. Clinical Scenario Examples

The scenarios below illustrate how the code, diagnosis, and modifiers should align to the clinical narrative and to common coverage logic.

Scenario 1: Primary care anemia evaluation

Patient: Fatigue, exertional dyspnea, pallor; history suggests iron deficiency risk.

Test: CBC with automated differential performed to evaluate anemia and rule in/out alternative causes (infection, marrow suppression).

Billing approach: Report 85025 once, link an appropriate anemia or symptom ICD-10 (as clinically supported).

Why it pays: Medicare’s NCD framework supports blood counts when used for diagnosis/management rather than screening .

Scenario 2: Oncology monitoring during chemotherapy

Patient: Active malignancy receiving chemotherapy; CBC is required to monitor neutropenia and thrombocytopenia risk before treatment cycles.

Test: CBC with differential prior to therapy.

Billing approach: 85025 once per medically indicated monitoring timepoint; ensure the record and claim reflect treatment/diagnosis rationale.

Why it pays: Contractor education emphasizes the need for documentation that supports laboratory use in oncology/hematology care, including orders and appropriate chart support .

Scenario 3: ED fever workup

Patient: Acute febrile illness; differential diagnosis includes bacterial pneumonia vs viral syndrome.

Test: CBC with differential to evaluate leukocytosis, left shift, and severity signals.

Billing approach: 85025 once, link symptom-based or final-diagnosis ICD-10 consistent with the clinical course.

Why it pays: Blood count testing is supported when used to evaluate symptomatic illness rather than performed without indication .

Scenario 4: Same-day repeat CBC for clinical change (modifier 91)

Patient: Hospitalized patient with suspected GI bleeding; baseline CBC in the morning, then hypotension and melena in the afternoon.

Test: Second CBC with diff to reassess hemoglobin/hematocrit and guide transfusion and escalation decisions.

Billing approach: First test: 85025. Second same-day test: 85025-91 with documentation of the clinical change and reason for repeat.

Why it pays: Modifier 91 distinguishes a medically necessary repeat from a duplicate claim line, consistent with “reasonable and necessary” logic under Medicare coverage expectations .

Scenario 5: CLIA-waived CBC device in a waived setting (modifier QW)

Setting: A clinic operating under a CLIA Certificate of Waiver performs CBC testing using a method specifically recognized as waived.

Test: CBC with differential performed on the waived method/device.

Billing approach: 85025-QW (when required by payer billing rules), with method documentation available and correct claim elements.

Why it pays: CLIA-waived status for specific tests is tracked through the CDC waived list and CMS guidance for waived test recognition and effective dates .

Across these examples, the consistent success pattern is:

• order and record clearly support why the CBC was needed;
• the ICD-10 on the claim matches that rationale, and;
• modifiers are used only when they reflect a real operational difference (repeat testing or waived method), not as a workaround for an edit.